| MSD Merck Sharp & Dohme AG - Keytruda subkutan 395 mg/2.4 ml, Injektionslösung | | 70253 | | 01 | | Keytruda subkutan 395 mg/2.4 ml | | Injektionslösung | | L01FF02 | | Pembrolizumab | | 01.06.2026 | | |
| | Composition | | pembrolizumabum 395 mg, berahyaluronidasum alfa, natrii chloridum corresp. natrium 23 µg, histidinum, histidini hydrochloridum monohydricum, methioninum, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad suspensionem pro 2.4 ml. | | Packungsbestandteile | | Solution injectable | | | | | | | | Principe actif | Concentr. |
|---|
| Pembrolizumabum | 395mg / 2.4ml |
| | BAG: Principe actif |
|---|
| Pembrolizumabum |
| | | | Agents auxilliaires |
|---|
| Berahyaluronidasum Alfa | | Histidin Hydrochloride Monohydrate | | Histidine | | Methionine | | Sodium Chlorure | | Polysorbatum 80 | | Saccharum |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | | 3933.27 | 4294.10 | A | LS | Non |
|
|
